Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2000 Jul;106(2):177-9.
doi: 10.1172/JCI10584.

Novel treatments for osteoporosis

E Canalis  1
Affiliations
Comment

Novel treatments for osteoporosis

E Canalis. J Clin Invest. 2000 Jul.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Two novel approaches to increasing bone mass. Bone mass reflects the relative rates of bone formation, mediated by osteoblasts, and of bone resorption, mediated by osteoclasts. Parathyroid hormone (PTH) has complex effects on bone mass, since it stimulates both of these processes, but treatment with estrogen, bisphoshponates, or other agents specifically blocks its effects on bone resorption. PTH promotes bone formation by several mechanisms, enhancing the proliferation of cells of the osteoblastic lineage, and promoting osteoblastic function. Some of these anabolic effects of PTH are mediated by IGF I. PTH secretion from the parathyroid gland is suppressed by signaling through the calcium receptor (CaR), which senses extracellular calcium levels. The new drug NPS 2143 acts by reducing the sensitivity of the calcium receptor to extracellular calcium, thereby enhancing PTH secretion and promoting osteoblast function. The drug SB 242784 acts by a complementary strategy, specifically inhibiting the vacuolar ATPase and thereby blocking osteoclast-mediated acidification of the bone matrix, which is required for bone resorption.
See this image and copyright information in PMC

Comment on

References

    1. Looker AC, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1997;12:1761–1768. - PubMed
    1. Ray NF, Chan JK, Thamer M, Melton LJ., III Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12:24–35. - PubMed
    1. Visentin L, et al. A selective inhibitor of the osteoclast V-H+-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats. J Clin Invest. 2000;106:309–318. - PMC - PubMed
    1. Gowen M, et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest. 2000;105:1595–1604. - PMC - PubMed
    1. Chatterjee D, et al. Sensitivity to vanadate and isoforms of subunits A and B distinguish the osteoclast proton pump from other vacuolar H+ ATPases. Proc Natl Acad Sci USA. 1992;89:6257–6261. - PMC - PubMed